Salute e Benessere
Coagulation Factor Deficiency Market - US to Have the Lion's Share Among the 7MM's | DelveInsight
Discover which therapies are expected to grab the major coagulation factor deficiency market share @
Coagulation factor deficiency diseases, also referred to as bleeding or clotting disorders, encompass a range of inherited or acquired conditions marked by the absence or malfunction of specific proteins essential for blood clotting. These proteins, known as coagulation factors, are vital for stopping bleeding by forming clots to close injured blood vessels.
There are several coagulation factors, labeled from I to XIII, that function in a complex and coordinated way to achieve hemostasis. Deficiencies in any of these factors can cause abnormal bleeding, varying in severity from mild to severe, depending on the specific factor affected and the extent of the deficiency.
Blood disorders are typically diagnosed by examining a range of symptoms and conducting various blood tests, which differ depending on the specific factor involved. Coagulation factor I deficiency is generally identified through a series of blood tests that measure the amount of fibrinogen in the blood. However, a low fibrinogen level can sometimes indicate liver or kidney disorders. For coagulation factor II, diagnosis is usually made using prothrombin time (PT) and partially activated thromboplastin time (aPTT) tests. Deficiency levels can range from 2% to 50% of normal, with patients at or near 50% usually experiencing normal or no bleeding issues.
The coagulation factor deficiency epidemiology section provides insights into the historical and current coagulation factor deficiency patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The coagulation factor deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
The treatment of coagulation factor deficiency typically involves replacing the missing factor in the blood, supplemented by additional therapies when bleeding persists. There are several treatments available for managing coagulation factor deficiencies. For moderate conditions like mucosal tract hemorrhage or heavy menstruation, physicians often prescribe antifibrinolytic drugs and hormones. Discovered after 1950, therapies such as help stabilize clots in areas like the mouth, bladder, and uterus. These adjunctive therapies are also beneficial for dental surgeries but are less effective for internal bleeding. These medications can be administered orally or by injection.
is an extended half-life glycopegylated factor VIII molecule used for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding.
This product has been evaluated in five prospective, multi-center clinical trials involving previously treated patients with severe hemophilia A and no history of inhibitors. The results of these trials have shown that the overall safety profile of ESPEROCT is comparable to other long-acting FVIII products, with no safety concerns identified after more than 5 years of clinical exposure.
, developed by , is designed for previously treated adults and adolescents (12 years and older) with hemophilia A (congenital Factor VIII deficiency). It is used for:
JIVI functions by replacing the deficient or absent factor VIII (FVIII) in patients with hemophilia A. It is also known as Damoctocog alfa pegol.
To know more about coagulation factor deficiency treatment guidelines, visit @
Discover more about coagulation factor deficiency drugs in development @
The coagulation factor deficiency market dynamics are expected to change in the coming years. The coagulation factor deficiency market is primarily driven by several key factors. The is a significant driver, as these conditions require ongoing management and treatment with coagulation factor concentrates. have led to the development of novel therapies, such as , which offer improved safety and efficacy profiles, further stimulating market growth.
Additionally, and the has led to increased demand for coagulation factor products.
for rare disease treatment, along with favorable reimbursement policies, are also contributing to market expansion. Moreover,
aimed at discovering new treatments and improving existing ones are expected to create lucrative opportunities in the market.
Furthermore, potential therapies are being investigated for the treatment of coagulation factor deficiency, and it is safe to predict that the treatment space will significantly impact the coagulation factor deficiency market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the coagulation factor deficiency market in the 7MM.
However several factors may impede the growth of the coagulation factor deficiency market. One of the primary challenges is the , particularly with recombinant and plasma-derived therapies, which limits accessibility for many patients. Additionally, there is a in many regions, particularly in low-income and rural areas, which leads to of these conditions.
also pose a significant barrier, as the approval process for new therapies is often lengthy and stringent, delaying the availability of potentially life-saving treatments. Furthermore, the coagulation factor deficiency market is constrained by , which impedes the discovery of innovative therapies. Lastly, the associated with the storage and distribution of these specialized products, which often require cold chain logistics, add another layer of complexity to coagulation factor deficiency market penetration and access.
Download the report to understand which factors are driving coagulation factor deficiency market trends @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the coagulation factor deficiency epidemiology trends.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key coagulation factor deficiency companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Hemophilia companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
View original content: https://www.prnewswire.co.uk/news-releases/coagulation-factor-deficiency-market--us-to-have-the-lions-share-among-the-7mms--delveinsight-302193215.html